APA

A L-Tweigeri T., AlSayed A., Alawadi S., Ibrahim M., Ashour W., Jaafar H., Abulkhair O., A L-Abdulkarim H., Khalid H. & Ajarim D. (20160517). A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. : Cancer chemotherapy and pharmacology.

Chicago

A L-Tweigeri Taher, AlSayed Adher, Alawadi Shafika, Ibrahim Mohamed, Ashour Wafaa, Jaafar Hassan, Abulkhair Omalkhair, A L-Abdulkarim Huda, Khalid Hassan and Ajarim Dahish. 20160517. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. : Cancer chemotherapy and pharmacology.

Harvard

A L-Tweigeri T., AlSayed A., Alawadi S., Ibrahim M., Ashour W., Jaafar H., Abulkhair O., A L-Abdulkarim H., Khalid H. and Ajarim D. (20160517). A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. : Cancer chemotherapy and pharmacology.

MLA

A L-Tweigeri Taher, AlSayed Adher, Alawadi Shafika, Ibrahim Mohamed, Ashour Wafaa, Jaafar Hassan, Abulkhair Omalkhair, A L-Abdulkarim Huda, Khalid Hassan and Ajarim Dahish. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. : Cancer chemotherapy and pharmacology. 20160517.